Gaze Bio Signs Deal To Supply Worried MSI Diagnostic Products To Georgia
Sep 19, 2024
Eye Biomaterials (CEO Park Hee-kyung) announced that 'U-TOP MSI detection kit' that evaluates microsatellite instability (MSI), which is essential for predicting the effectiveness of immuno-oncology drugs, is exported to Georgia.
The company has decided to supply the diagnostic kit to L Company of Georgia (Europe, Georgia) for three years until the first half of 2027. Company L is a clinical biochemical, immunological, blood bank, and molecular diagnostic company established in 2015 and has business alliances with overseas molecular diagnostic companies such as AmoyDx in China and Erba Diagnostics in Germany.
The U-TOP MSI detection kit is a product that diagnoses MSI essential for screening and administering immuno-cancer drugs (immune checkpoint inhibitors) such as 'Kytruda' (component name Pembrolizumab). MSI is a phenomenon in which mutations accumulate due to the failure of the function of DNA mismatch repair gene (dMMR gene) to complement the base made by mistake during DNA replication. It has been observed in various solid cancers such as colon cancer, stomach cancer, endometrial cancer, ovarian cancer, pancreatic cancer, biliary tract cancer, lung cancer, bladder cancer, and prostate cancer, and is widely used as a diagnostic indicator.
In the clinical field, MSI diagnosis is being conducted with the aim of screening patients before administration by predicting therapeutic responsiveness following administration of immuno-cancer drugs. In order to reduce unnecessary administration of patients and waste of high drug prices, it is becoming an essential diagnostic test performed before administration of immuno-oncology drugs. In the case of high frequency microsatellite instability (MSI-H), it is reported that immune anticancer drugs have excellent therapeutic responsiveness.
The MSI diagnostic product of Sisang Bio was approved by the Ministry of Food and Drug Safety as an in vitro diagnostic medical device for four cancers (colorectal cancer, gastric cancer, endometrial cancer, and ovarian cancer). These four carcinomas belong to cancers that the National Cancer Network (NCCN) recommends MSI or Mismatch Repair (MMR) tests through guidelines.
Park Hee-kyung, CEO of Gisaeng Bio, said "We are currently registering U-TOP MSIkit products in Georgia, and the actual product launch date is expected in October.""As the first polymerase chain reaction (PCR)-based MSI analysis product in Georgia, it will be able to effectively target the market based on its low price and significantly reduce analysis time compared to existing products based on capillary sequencing or next-generation sequencing (NGS) based on DNA templates. "
The company has decided to supply the diagnostic kit to L Company of Georgia (Europe, Georgia) for three years until the first half of 2027. Company L is a clinical biochemical, immunological, blood bank, and molecular diagnostic company established in 2015 and has business alliances with overseas molecular diagnostic companies such as AmoyDx in China and Erba Diagnostics in Germany.
The U-TOP MSI detection kit is a product that diagnoses MSI essential for screening and administering immuno-cancer drugs (immune checkpoint inhibitors) such as 'Kytruda' (component name Pembrolizumab). MSI is a phenomenon in which mutations accumulate due to the failure of the function of DNA mismatch repair gene (dMMR gene) to complement the base made by mistake during DNA replication. It has been observed in various solid cancers such as colon cancer, stomach cancer, endometrial cancer, ovarian cancer, pancreatic cancer, biliary tract cancer, lung cancer, bladder cancer, and prostate cancer, and is widely used as a diagnostic indicator.
In the clinical field, MSI diagnosis is being conducted with the aim of screening patients before administration by predicting therapeutic responsiveness following administration of immuno-cancer drugs. In order to reduce unnecessary administration of patients and waste of high drug prices, it is becoming an essential diagnostic test performed before administration of immuno-oncology drugs. In the case of high frequency microsatellite instability (MSI-H), it is reported that immune anticancer drugs have excellent therapeutic responsiveness.
The MSI diagnostic product of Sisang Bio was approved by the Ministry of Food and Drug Safety as an in vitro diagnostic medical device for four cancers (colorectal cancer, gastric cancer, endometrial cancer, and ovarian cancer). These four carcinomas belong to cancers that the National Cancer Network (NCCN) recommends MSI or Mismatch Repair (MMR) tests through guidelines.
Park Hee-kyung, CEO of Gisaeng Bio, said "We are currently registering U-TOP MSIkit products in Georgia, and the actual product launch date is expected in October.""As the first polymerase chain reaction (PCR)-based MSI analysis product in Georgia, it will be able to effectively target the market based on its low price and significantly reduce analysis time compared to existing products based on capillary sequencing or next-generation sequencing (NGS) based on DNA templates. "
|
bellho@sportschosun.com
